Company intelligence / Profile preview
KinDex Pharmaceuticals
Boston, Massachusetts, United Statesdnb.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
01
Overview
KinDex Pharmaceuticals is developing small molecule therapeutics targeting metabolic and inflammatory pathways. Its lead candidate, KDT‑501—a dual GPR120/PPARγ modulator—is in preclinical development for polycystic ovary syndrome. Other pipeline assets target inflammation and obesity via taste receptor modulation. No clinical efficacy data have been reported as of the latest updates.
- Therapeutic areas
- Women's HealthImmunologyEndocrinology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on KinDex Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KinDex Pharmaceuticals.